Managers / Q1 2021 · view latest →
Burrage Capital Management LLC
CIK 0001796461 · 314 COMMONWEALTH AVENUE, #4, BOSTON, MA, 02115 · 617-410-4770
Summary
Burrage Capital Management LLC reported $123M in U.S.-listed holdings across 27 positions for Q1 2021.
Its largest position, PLX, represents 7.7% of the portfolio.
Compared with Q4 2020, the fund opened 7 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 83.8% · $103M
- Other · 16.2% · $20M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ESSA PHARMA INC | NEW | +237.4K | 237.4K | +$7M | $7M |
| HRMYHARMONY BIOSCIENCES HLDGS IN | NEW | +150.0K | 150.0K | +$5M | $5M |
| CARA THERAPEUTICS INC | NEW | +180.0K | 180.0K | +$4M | $4M |
| TRICIDA INC | NEW | +658.9K | 658.9K | +$3M | $3M |
| GERNGERON CORP | NEW | +1.91M | 1.91M | +$3M | $3M |
| TURNING POINT THERAPEUTICS I | NEW | +700 | 700 | +$861,000 | $861,000 |
| INTELLIA THERAPEUTICS INC | NEW | +630 | 630 | +$46,000 | $46,000 |
| BDTXBLACK DIAMOND THERAPEUTICS I | ADDED | +75.6K | 110.4K | +$2M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2021
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2021 | $0 | 1 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $100M | 22 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $123M | 27 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $131M | 25 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $127M | 27 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $143M | 26 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $102M | 31 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $149M | 29 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.